These 4 Healthcare Stocks Are Gaining Speed
CORAL GABLES, FL / ACCESSWIRE / December 27, 2018 / With the new year less than one week away, the healthcare industry is effervescent with excitement as companies work towards designing new methods and technologies to dramatically improve care options available to consumers. As medical experts and scientists discover diseases, companies are ready to meet the challenge head-on by developing advanced drug treatment with the patient's best interest at the core of it all. Premier Health Group (OTC:PHGRF) (CSE:PHGI), BioXcel Therapeutics Inc (BTAI), Axsome Therapeutics Inc (AXSM), and Adial Pharmaceuticals are 4 healthcare stocks representing companies dead-set on fostering the best possible care options and products in their sector.
Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company you may not have heard of, but may want to look into as they break new ground on inventive approaches to products and treatments previously determined to be unchangeable. Back in the day, if an individual needed primary care, they had to make time to see their primary care physician. Premier Health Group (OTC:PHGRF) (CSE:PHGI)'s subsidiary, HealthVue, is currently developing propertiary technology to deliver healthcare though a network of interconnected primary care clinics couple with AI integration and telemedical technologies, resulting in improved access to care options from the comfort of one's own home.
Recent statistics indicate that the Company currently supports a member-base of over 100,000 active patients in their network, with plans to increase membership on a global scale.
Towards the end of last week, the Company announced that had signed a binding letter of intent agreement to acquire all outstanding securities of Cloud Practice Inc.
Dr. Essam Hamza, CEO of Premier Health, commented on the LOI, saying that, "We are ecstatic at the opportunity to build on our patient-centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare..."
For More Information On Premier Health Group, Click Here
BioXcel Therapeutics, Inc (BTAI), a clinical stage biopharmaceutical company utilizing artificial intelligence technologies to design new medicines for the field of immuno-oncology, announced on Thursday that it had been granted Fast Track Designation for its investigational drug BXCL501 by the U.S. FDA.
For those unfamiliar, FDA's Fast Track program is designed to provide certain benefits for new drugs that treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. The designation provides the opportunity for more frequent meetings with the FDA over the course of development.
Dr. Vimal Mehta, Chief Executive Officer of BTAI, commented, ''Fast track designation for BXCL501 highlights FDA's recognition of our investigational therapy as a possible treatment for acute agitation associated with schizophrenia, bipolar disorder and dementia. This regulatory milestone will help facilitate clinical development and expedite regulatory review of BXCL501, bringing us closer to potentially delivering an optimal therapeutic solution effective for both patients and caregivers.''
For More Information On BioXcel Therapeutics, Inc., Click Here
Axsome Therapeutics, Inc (AXSM), one of several clinical-stage biopharmaceutical companies working on novel therapies for managing disorders related to the central nervous system, provided their most recent clinical update for its CNS treatment options in time for the new year. Following this update, the Company's shares jumped 1.46% in early trading on Thursday to $2.08 per share.
In a press release regarding the clinical update, the Company shared that, to date, just under 90% of the target number of subjects for their treatment resistant depression trials have demonstrated topline results after participating in STRIDE-1, a multi-center, randomized, double-blind, controlled trial in which subjects with TRD are randomized to treatment with AXS-05 or bupropion.
For More Information on Axsome Therapeutics, Inc., Click Here
Adial Pharmaceuticals, Inc, (ADIL) announced on Monday that the holder of the sole remaining, outstanding convertible note has fully converted the balance of the note into common shares of the Company. As previously reported, the convertible note had a face value of $325,000 and was a convertible into 162,500 shares of common stock, according to a press release regarding the matter.
William Stilley, CEO of Adial Pharmaceuticals, commented, "As we position Adial for continued success in 2019, I am pleased to report that we have now completed the retirement of all outstanding debt instruments by facilitating the conversion of this note obligation. We appreciate the support and confidence this shareholder has provided leading up to and since our recent IPO. Looking ahead, our goal is to drive shareholder value in the coming year by achieving key clinical milestones, while maintaining a clean capital structure and healthy balance sheet.''
For More Information On Adial Pharmaceuticals, Inc., Click Here
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid''500,000'' shares of restricted common shares. We were paid an additional $100,000 (CASH) for continued coverage. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
CONTACT:
SOURCE: Stock Price
